How Flagship's newest startup is pursuing a 'holy grail' of biotech

The latest biotech spawned from Flagship Pioneering ’s in-house incubator boasts a veritable dream team of executives and board members. And like others in the Cambridge venture firm’s arsenal, it’s dreaming big. Flagship launched Sigilon Therapeutics on Tuesday with a $23.5 million round. The company, which was co-founded by renowned MIT prof essors Bob Langer and Daniel Anderson, is trying to develop a new class of “living therapeutics” — engineered cells that can fight a range of disorders…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Source Type: news